Medpace Beats on Q3 EPS, Authorizes New $1.0B Buyback Through 2028
MEDP sits 70% above its 52-week low of $373 on elevated volume (3.4× avg).
Summary
Medpace reported Q3 EPS of $4.84 on $716.0M revenue with margins expanding, and the board replaced its remaining $527.0M repurchase authorization with a new $1.0B program through 2028.
Key Events · Earnings and Guidance · MEDP
-
Q3 EPS $4.84, Revenue $716.0M
Revenue rose 8.5% year over year and GAAP net income was $137.5M, lifting net income margin to 19.2% from 16.8%.
-
New $1.0B Buyback Through 2028
Board terminated the prior authorization with $527.0M remaining and approved up to $1.0B of repurchases until December 31, 2028, funded from cash on hand.
-
FY2026 Guidance: $17.97-$18.32 EPS
Revenue forecast of $2.835B-$2.855B (12.0%-12.8% growth), EBITDA of $638.0M-$652.0M, and GAAP net income of $514.0M-$524.0M; guidance excludes any buybacks after September 30.
-
Awards and Backlog Growing
Net new business awards were $873.4M, up 10.6%, and backlog reached $3,167.2M, up 5.6% year over year.
Analysis · MEDP · Industrial Applications And Services
Medpace delivered Q3 EPS of $4.84 on $716.0M revenue, with net income margin expanding to 19.2% from 16.8% and EBITDA margin to 24.0% from 22.5%. The bigger news buried in the release is capital allocation: the board terminated the old authorization with $527.0M left and replaced it with a $1.0B program running to December 31, 2028, funded from $705.3M of cash. That is a large commitment relative to a company that bought back nothing in Q3, and it sits against a backdrop of heavy insider selling — Chairman/CEO August Troendle sold roughly $125M over six weeks per the September 13D/A. Full-year guidance of $17.97-$18.32 EPS and $638M-$652M EBITDA frames the rest of the year. The conference call is October 22.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1563 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDP was trading at $635.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $18.5B. The 52-week trading range was $373.00 to $677.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.